18F-DOPA II - PET Imaging Optimization

Who is this study for? Patients with Congenital Hyperinsulinism, Neuroblastoma, Neuroendocrine Tumors, Parkinson's Disease, or Brain Glioma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism. 2. Pediatric patients (less than 18 years old) with neuroblastoma. 3. Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor. 4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia. 5. Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors. Image optimization (the primary study objective) and gallbladder activity pattern (the secondary objective) will be evaluated.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Pediatric patients (less than 18 years old) with congenital hyperinsulinism.

• Pediatric patients (less than 18 years old) with neuroblastoma.

• Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor.

• Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia.

• Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors.

Locations
Other Locations
Canada
WC Mackenzie Health Science Centre / University of Alberta Hospital
RECRUITING
Edmonton
Contact Information
Primary
Jonathan Abele, MD
jabele@ualberta.ca
1-780-407-6907
Time Frame
Start Date: 2021-01-20
Estimated Completion Date: 2026-07
Participants
Target number of participants: 800
Treatments
Experimental: 18F-DOPA injection
All enrolled participants will receive an intravenous injection of the investigational 18F-DOPA radiopharmaceutical
Sponsors
Leads: University of Alberta

This content was sourced from clinicaltrials.gov